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Background: Mutations in the SHANK genes, which encode postsynaptic scaffolding proteins, have been linked to a
spectrum of neurodevelopmental disorders. The SHANK genes and the schizophrenia-associated microRNA-137 show
convergence on several levels, as they are both expressed at the synapse, influence neuronal development, and have a
strong link to neurodevelopmental and neuropsychiatric disorders like intellectual disability, autism, and schizophrenia.
This compiled evidence raised the question if the SHANKs might be targets of miR-137.
Methods: In silico analysis revealed a putative binding site for microRNA-137 (miR-137) in the SHANK2 3′UTR, while this
was not the case for SHANK1 and SHANK3. Luciferase reporter assays were performed by overexpressing wild type and
mutated SHANK2-3′UTR and miR-137 in human neuroblastoma cells and mouse primary hippocampal neurons. miR-
137 was also overexpressed or inhibited in hippocampal neurons, and Shank2 expression was analyzed by quantitative
real-time PCR and Western blot. Additionally, expression levels of experimentally validated miR-137 target genes were
analyzed in the dorsolateral prefrontal cortex (DLPFC) of schizophrenia and control individuals using the RNA-Seq data
from the CommonMind Consortium.
Results: miR-137 directly targets the 3′UTR of SHANK2 in a site-specific manner. Overexpression of miR-137 in mouse
primary hippocampal neurons significantly lowered endogenous Shank2 protein levels without detectable influence
on mRNA levels. Conversely, miR-137 inhibition increased Shank2 protein expression, indicating that miR-137 regulates
SHANK2 expression by repressing protein translation rather than inducing mRNA degradation.
To find out if the miR-137 signaling network is altered in schizophrenia, we compared miR-137 precursor and miR-137
target gene expression in the DLPFC of schizophrenia and control individuals using the CommonMind Consortium
RNA sequencing data. Differential expression of 23% (16/69) of known miR-137 target genes was detected in the DLPFC
of schizophrenia individuals compared with controls. We propose that in further targets (e.g., SHANK2, as described in this
paper) which are not regulated on RNA level, effects may only be detectable on protein level.
Conclusion: Our study provides evidence that a direct regulatory link exists between miR-137 and SHANK2 and supports
the finding that miR-137 signaling might be altered in schizophrenia.
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microRNAs are small non-coding, single-stranded RNA
molecules that regulate gene expression by binding to the
3′UTRs of their target mRNAs through base pairing of
their 6–8-nucleotide long seed region. They either initiate
mRNA degradation or inhibit protein translation [1, 2].
Regulation of gene expression in the nervous system is
highly complex and is fine-tuned by microRNAs [3]. In
neurons, mRNAs and microRNAs are compartmentalized
to specific subcellular regions, like the synaptodendritic
compartment, to regulate local protein synthesis in
response to neuronal stimuli [4].
microRNA-137 (miR-137) is enriched in the human and
mouse brain [5], especially in cortical regions and in the
hippocampus [6]. It plays a role in cell proliferation and
differentiation and is present at the synapse [6, 7]. Further-
more, it regulates neuronal maturation, dendritic morpho-
genesis, and spine development [8]. Homozygous knockout
of Mir137 is embryonically lethal in mice, indicating that
embryonic development is dependent on at least one func-
tional allele [9]. This emphasizes the importance of miR-
137 in early developmental processes.
Genetic alterations ofMIR137 have been associated with
neurodevelopmental disorders. The rare chromosomal
microdeletion 1p21.3 encompassing MIR137 and DPYD
was identified in individuals with intellectual disability
(ID), comorbid with autism spectrum disorder (ASD), and
obesity [6, 10, 11]. In addition, 19/65 (29%) highest ranked
ASD risk genes in the Simons Foundation Autism Re-
search Initiative gene database [12, 13] (URL: https://sfari.
org/resources/sfari-gene#refs, accessed May 2017) are pre-
dicted or confirmed miR-137 targets (Additional file 1:
Table S1). miR-137 target genes are enriched among ASD
risk genes (29%, CI 18.6–41.8%) compared with the
random frequency (2.9%, predicted in the miRDB database
[14]; CI 2.7–3.2%, 525/17860) (P ≤ 0.000001, Fisher’s exact
test, two-sided). Furthermore, the MIR137 gene has been
reported as a schizophrenia (SCZ) susceptibility locus
because the common SNP rs1625579, located in an intron
of MIR137, was associated with SCZ in several studies
[15–18]. Putative miR-137 targets are enriched in SCZ risk
loci [18], suggesting that convergent pathways connected
by this microRNA contribute to SCZ etiology. A meta-
analysis of SNP data across five different neuropsychiatric
disorders identified a shared risk locus association with
SCZ and ASD [19]. Taken together, these findings indicate
that deregulation of miR-137 is the key to various psychi-
atric and neurodevelopmental disorders.
SHANK proteins (SHANK1, SHANK2, and SHANK3)
are postsynaptic scaffolding proteins with an important
role in the formation, maintenance, and function of
synapses in glutamatergic neurons of the brain [20].
SHANK genes converge with miR-137 on several levels:
(i) both are expressed at the synapse, (ii) both influencedendrite and spine formation in glutamatergic neurons
[8, 21], and (iii) both have a strong link to neurodevelop-
mental and neuropsychiatric disorders like ID, ASD, and
SCZ [18, 22, 23]. This suggests that SHANK genes might
be targets of miR-137.
Methods
Luciferase assays
To validate a predicted miR-137 binding site in SHANK2,
luciferase reporter assays were carried out in human SH-
SY5Y cells and mouse primary hippocampal neurons. The
wild type SHANK2-3′UTR was cloned into the psi-
CHECK™-2 vector (Promega, Mannheim, Germany) after
PCR amplification on human genomic DNA from a healthy
individual. PCR primers introduced the restriction sites
(XhoI) which were used to introduce the PCR product into
the psiCHECK™-2 vector via Gibson® Assembly (New
England BioLabs, Frankfurt, Germany). Mutagenesis of the
miR-137 binding site was performed on the wild type
construct by PCR with the original cloning primers and
mutagenesis primers, assembled using the SLiCE cloning
system [24]. The sequence of wild type and mutated
SHANK2-3′UTR was validated by Sanger sequencing.
Primer sequences are given in Additional file 1: Table S2.
The SH-SY5Ycells were seeded in antibiotic-free medium
and transfected after 24 h with 200 ng of empty psi-
CHECK™-2 vector and wild type or mutated SHANK2 3′
UTR constructs with 12 nM miR-137 or control mimics
(mirVana® miRNA hsa-miR-137 mimic MIMAT0000429
and Pre-miR™ miRNA Precursor Molecules Negative Con-
trol #2, AM17111, Thermo Fisher Scientific, Darmstadt,
Germany) in technical triplicates using Lipofectamine®2000
(Thermo Fisher Scientific, Darmstadt, Germany). miRNA
mimics are small, double-stranded RNA molecules which
mimic endogenous, mature microRNA molecules when
introduced into the cells. Luciferase activity was measured
48 h posttransfection using the dual luciferase reporter
assay system (Promega) and the luminometer Centro
LB960 (Berthold Technologies, Bad Wildbad, Germany).
Renilla luciferase activity was normalized against firefly
luciferase activity, and the background was subtracted by
normalization to the empty psiCHECK™-2 vector activity.
Primary hippocampal neurons were transfected on day
in vitro (DIV) 5 using the same experimental setup as in
the SH-SY5Y cells for the mimic experiments with
25 nM mimics. The amount of miR-137 mimics had to
be optimized for each cell type separately. For the
inhibitor experiments, the primary mouse hippocampal
neurons were treated with 25 nM miR-137 or power
inhibitor control (miRCURY LNA™ Power microRNA
hsa-miR-137 4101446-111 or negative control B 199007-
111 inhibitor 5′-Fluorescein-labeled, Exiqon, Vedbaek,
Denmark) added drop-wise to the cells on DIV5. The
miR-137 power inhibitor sequesters both the human
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venting it from binding to its targets. The control inhibi-
tor does not influence miR-137 and was used to control
for unspecific effects of the treatment. Experimental
conditions were identical between both groups regarding
cell number and cell types (Additional file 1: Figure S1).
The cells were transfected with the luciferase reporter
constructs with Lipofectamine®2000 on DIV6. Luciferase
activity was measured 48 h posttransfection as described
above.
Cell culture
The SH-SY5Y cells were obtained from the DSMZ (Leibniz
Institute German collection of Microorganisms and Cell
Cultures, Braunschweig, Germany, ACC209). The cells
were kept in supplemented Dulbecco’s Modified Eagle’s
Medium (DMEM) (15% fetal bovine serum (FBS), 1% peni-
cillin/streptomycin (P/S), 1% non-essential amino acids).
Hippocampal cultures were prepared from gestating CD-1®
IGS mice (Charles River, Sulzfeld, Germany) at embryonic
stage 15.5. The cells were seeded in plating media (DMEM
+ 10% FBS, 0.25% P/S, 2 mM L-glutamine) on poly-L-
ornithine (Sigma Aldrich, Schnelldorf, Germany) coating.
On DIV 1, a complete medium change to supplemented
Neurobasal medium (Gibco® Neurobasal® media + 2%
Gibco®B-27® supplement, 0.25% P/S, 0.5 mM L-glutamine)
was performed. On DIV3, a half medium change was
carried out with 5 μM cytosine β-D-arabinofuranoside in
supplemented Neurobasal media, except for the cells that
were harvested on DIV3. From DIV5 until the final culture
day, a half medium change was performed with supple-
mented Neurobasal media every other day, except for the
cells that were transfected or harvested.
Nucleofection of mouse hippocampal cells
Hippocampal cultures were transfected with the optimized
hsa-miR-137 mimic concentration of 300 nM and negative
miRNA control on DIV5 using the AD1 4D-Nucleofector™
Y Unit system (Lonza, Basel, Switzerland) according to
manufacturer’s instructions. Cell types and cell numbers
showed no difference after nucleofection between the two
conditions (Additional file 1: Figure S1).
RT-qPCR
To determine the effect of miR-137 on endogenous
Shank2 expression real-time quantitative PCR (RT-qPCR)
was performed. For the quantification of Shank2 expres-
sion, RNA was isolated from mouse primary hippocampal
neurons (DIV8) 72 h after transfection with using the
Quick-RNA™ MicroPrep Kit (Zymo Research, Freiburg,
Germany) and was transcribed with the SuperScript®
VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific,
Darmstadt, Germany). RT-qPCR was performed to quan-
tify Shank2 expression normalized against two referencegenes (Gapdh and Hprt1). Primer sequences are provided
in Additional file 1: Table S2.
The RNAqueous®-Micro Total RNA Isolation Kit
(Thermo Fisher Scientific) was used for total RNA isola-
tion. Ten nanograms of total RNA were transcribed using
the miRCURY LNA™ microRNA PCR Universal cDNA
synthesis Kit (Exiqon) with a spike-in loading control
according to manufacturer’s instructions. RT-qPCR was
performed with miRCURY LNA™ microRNA PCR
ExiLENT SYBR® Green PCR sets for hsa-miR-137, U6,
and spike-in (Exiqon), measuring the endogenous miR-
137 expression profile in primary hippocampal neurons
over a time period of 11 DIV. miR-137 expression levels
were analyzed with the same method using 21 different
human tissue RNA samples (specified in Additional file 1:
Table S3).
Western blot analysis
To determine the effect of miR-137 on Shank2 protein
expression, cellular protein was isolated using RIPA buffer
from cell cultures on DIV10, and the lysates were run on
Novex™WedgeWell™4–12% Tris-Glycine Gels (Thermo
Fisher Scientific) and then blotted onto a PVDF mem-
brane (Immobilon-FL, Millipore, Billerica, Massachusetts,
USA) as recommended by the manufacturer. Primary
antibodies anti-beta-III-tubulin (mouse, G7121 Promega)
and anti-Shank2 (rabbit, ABIN656710 antibodies-online)
were used followed by the secondary IRDye 680 donkey
anti-mouse and IRDye 800CW donkey anti-rabbit anti-
bodies (1706515 and 1706516, respectively, Li-COR). The
membrane was scanned with the Odyssey® Infrared
Imaging System (Li-COR) and quantified using ImageJ
software39. Shank2 was normalized to beta-III-tubulin. All
experiments were performed sequentially over several
weeks. Hippocampal neurons were isolated and differenti-
ated at different time points.
CommmonMind data
The tissue used for RNA sequencing was obtained from
the following institutes: Mount Sinai School of Medicine,
University of Pennsylvania, University of Pittsburgh,
National Institute of Mental Health, F. Hoffman-La Roche
Ltd., Takeda Pharmaceuticals Company Limited, Sage
Bionetworks, Duke University, and University of North
Carolina. Generation and analysis of the RNA sequencing
data has been previously described in detail by the
CommonMind Consortium [25]. To analyze the expres-
sion levels of the validated miR-137 target genes and miR-
137 precursor, we selected the average expression levels,
the log2-fold change and the P values for the respective
genes published on https://synapse.org in the “Results
Explorer” on the “CommonMind Consortium Knowledge
Portal” (data accessed June 2017). A weighted linear
regression analysis had been performed for each gene
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each gene, the SCZ disease status coefficient had been
statistically tested for being nonzero, implying an
estimated effect for SCZ, above and beyond any other
effect from covariates. This test produced a t statistic and
a corresponding P value. Details about the statistical
analysis are provided in the CommonMind Consortium
paper [25].Selection of experimentally validated miR-137 targets and
network analysis
Validated targets of miR-137 were collected from miR-
TarBase (http://mirtarbase.mbc.nctu.edu.tw/, accessed
January 2017) and PubMed (https://www.ncbi.nlm.nih.
gov/pubmed/, accessed January 2017) database searches.
miRTarBase targets were included if they were catego-
rized as “strong evidence,” i.e., confirmed by experimen-
tal methods of validation including luciferase reporter
assay, RT-qPCR, and/or Western blot analysis. Targets
from the PubMed database search were considered as
validated if a direct link was established by luciferase
reporter assay, RT-qPCR, and/or Western blot analysis.
Duplicates between databases were removed. A total of
71 validated targets were obtained; most of them have
been investigated in cancer cells, whereas only 12 targets
have been validated in neurons (details are shown in
Additional file 1: Table S4). RNA sequencing data for
the miR-137 target genes HCRT, SLC6A3, and SNAI1
was not available in the CommonMind dataset. The
target gene network was analyzed through the use of
QIAGEN’s Ingenuity®Pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity).Statistical analysis
Statistical analyses were performed using the SPSS software
(IBM Corp.; IBM SPSS Statistics for Windows, Version 22.
0.; Armonk, NY, USA). Two-way ANOVAs were performed
considering the influence of the experiment and the
respective condition. The data is shown as mean ± SEM.
The validated miR-137 target genes (including SHANK2)
were ranked according to their point-wise P values from
the CommonMind analysis, and the Benjamini-Hochberg
method was used to correct for multiple testing with a false
discovery rate of 10% (Additional file 1: Table S5). A two-
sided Χ2 test with Yates correction was used to compare the
expression of validated target genes of miR-137 and five
control microRNAs. The differentially expressed targets of
the five control microRNAs were pooled together. Genes
that were targets of more than one control microRNA were
only counted once. Eight target genes that were not
differentially expressed in SCZ and control individuals
overlapped between miR137 and the five controls and were
excluded from analysis.Results
miR-137 directly targets the SHANK2 3′UTR
In silico analysis (TargetScanHuman Release 7.1 [26]) of
all three SHANK genes identified a single, highly con-
served binding site for miR-137 (MIMAT0000429) in the
3′UTRof SHANK2 (ENST00000449833.2, Additional file 1:
Figure S2A), suggesting that this microRNA has the po-
tential to bind SHANK2 mRNA. The analysis of miR-137
expression in 21 different human tissue samples revealed
high expression in the central nervous system and mar-
ginal expression in other tested organs (Additional file 1:
Figure S3). miR-137 was highly expressed in the fetal
brain, and expression remained strong in the adult hippo-
campus, thalamus, and striatum. These are brain regions
where SHANK2 is also expressed [27, 28].
To validate the predicted miR-137 binding site in
SHANK2, we carried out luciferase reporter assays.
Human neuroblastoma cells (SH-SY5Y) were transfected
with a dual luciferase reporter plasmid (psiCHECK™-2)
containing either the wild type (wt) SHANK2 3′UTR
sequence or a miR-137 binding site-mutated 3′UTR
(mut) together with either miR-137 or negative control
miRNA mimics (Fig. 1a). The SH-SY5Y cells co-
transfected with SHANK2 wild type 3′UTR reporter and
miR-137 showed a 38% decrease in luciferase activity
compared with the negative control (Fig. 1b; ***P = 5.2 ×
10−9, two-way ANOVA). In contrast, no difference was
observed between miR-137 and negative control miRNA
for the mutated 3′UTR. This indicated that miR-137
specifically binds the target site, as mutation of the seed
region in the miR-137 binding site eliminated the robust
downregulatory effect of miR-137.
Alterations in the microRNA machinery have been
described in various cancers [29]; therefore, we further
analyzed the regulatory effect of miR-137 on Shank2
expression in mouse primary hippocampal neurons. These
neurons express Shank2 and Mir137, and the miR-137
binding site is conserved in the mouse Shank2 3′UTR
(Additional file 1: Figure S2B). We co-transfected SHANK2
wild type 3′UTR reporter and miR-137 and observed a
28% decrease in luciferase activity compared with the
negative control (*P = 0.022, two-way ANOVA). In con-
trast, no effect was seen with the mutated 3′UTR (Fig. 1c).
We concluded that miR-137 directly and specifically targets
the predicted binding site in the 3′UTR of SHANK2 in the
SH-SY5Y cells and primary hippocampal neurons.
miR-137 regulates Shank2 protein levels
We overexpressed miR-137 and negative control miRNA
mimics in mouse hippocampal neurons to determine the
effect on endogenous Shank2 expression. miR-137 overex-
pression did not alter endogenous Shank2 mRNA levels
in hippocampal neurons (Fig. 1d). However, Western
blotting revealed a 29% reduction of Shank2 protein
Fig. 1 a Alignment of miR-137 with the human SHANK2-3′UTR (NM_012309) wild type and mutated seed sequence. b Luciferase activity using
the wild type (wt) and mutated (mut) 3′UTR of SHANK2 co-transfected with hsa-miR-137 mimic or control miRNA in the SH-SY5Y cells. The data
was normalized to the empty psiCHECK™-2 vector, relative to the control miRNA. c Luciferase gene activity was measured 48 h after co-transfection of
wild type and mutated SHANK2 3′UTR with hsa-miR-137 or control miRNA in primary mouse hippocampal cultures (DIV5). d Relative SHANK2 expression
levels were measured by RT-qPCR. Primary mouse hippocampal neurons were transfected with either hsa-miR-137 or control miRNA. RNA was harvested
48 h posttransfection (n= 3 experiments). e Western blot of primary mouse hippocampal neurons 5 days posttransfection with hsa-miR-137 or control
miRNA. Cropped pictures indicate Shank2 and βIII-tubulin expression and the full length blots are presented in Additional file 1: Figure S4A. The data was
normalized to the control miRNA. Bar plots show mean ± SEM; ***P< 0.001, *P< 0.05 two-way ANOVA; b, c, and e (n= 5 experiments)
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pression in hippocampal neurons compared with the nega-
tive control miRNA mimics (Fig. 1e).
To determine whether endogenous miR-137 is able to
regulate Shank2 expression, we carried out luciferase assays
and Western blot experiments in mouse primary hippo-
campal neurons after inhibition of miR-137 with a targeted
miRCURY LNA™ Power microRNA inhibitor or treatment
with a microRNA inhibitor control. First, we analyzed the
endogenous miR-137 expression profile in primary hippo-
campal neurons. Expression levels remained constant until
5 days in vitro (DIV5), increased six-fold between DIV5
and DIV8, and remained high until DIV11 (Fig. 2a). Next,we treated cells with a miR-137 inhibitor or control inhibi-
tor on DIV5, shortly before miR-137 reaches its highest
endogenous expression levels. We performed luciferase
reporter assays on DIV6 using SHANK2 3′UTR luciferase
constructs. miR-137 inhibition increased the relative lucifer-
ase activity for the SHANK2 wt reporter construct by 70%
(*P = 0.044, two-way ANOVA) compared with the control
(Fig. 2b). Endogenous miR-137 was sequestered by the
inhibitor; therefore, the regulatory effect on the SHANK2
3′UTR was lost and luciferase activity was increased. This
was not observed with the mutated SHANK2 3′UTR
reporter construct. Finally, we analyzed the consequences
of endogenous miR-137 inhibition on Shank2 protein levels
Fig. 2 a Expression profile of miR-137 in mouse primary hippocampal cultures over 11 days in vitro (DIV). The graph shows data relative to DIV3
(n = 3). b Luciferase assay in primary mouse hippocampal neurons treated with hsa-miR-137 or control power inhibitors at DIV5. Luciferase reporter
constructs were transfected at DIV6, and luciferase activity was measured after 48 h. c Western blot with lysate from primary mouse hippocampal
neurons treated with hsa-miR-137 or control power inhibitor at DIV5 and protein was harvested after 5 days. Cropped pictures indicate Shank2 and
βIII-tubulin expression, and the full length blots are presented in Additional file 1: Figure S4B. Bar plots show mean ± SEM; *P < 0.05 two-way ANOVA;
(n = 5 experiments)
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increased endogenous Shank2 protein expression by 24%
compared with control inhibitor (*P = 0.016, two-way
ANOVA) (Fig. 2c).
Expression of miR-137 precursor and validated miR-137
target genes in the DLPFC of SCZ and control individuals
Previous studies have pointed to cellular, neurochemical
and functional abnormalities in the dorsolateral prefrontal
cortex (DLPFC) of SCZ individuals, implicating a role of
this particular brain region in the pathophysiology of SCZ
[30]. In the DLPFC, SHANK2 and miR-137 are both
expressed [27, 31] and we aimed to identify whether miR-
137, SHANK2, and other known miR-137 targets are differ-
entially expressed in the DLPFC of SCZ individuals
compared to controls. We used a gene expression resource
that provides RNA sequencing data in the DLPFC of de-
ceased individuals with SCZ (n = 258) and control (n = 279)
subjects (CommonMind Consortium) [25]. Out of 16,423
genes analyzed, 693 genes were differentially expressed
between SCZ and control individuals; 332 were upregulated
and 361 were downregulated [25]. The data for miR-137
precursor but not mature miR-137 expression levels were
available in this data set. We examined the data for miR-
137 precursor expression and found that it did not differ
between SCZ and control individuals (MIR137HG,
ENSG00000231269, P = 0.699). Next, we focused on the
miR-137 signaling network and analyzed the expression of
69 known miR-137 target genes (68 validated targets from
previously published studies summarized in Additional file 1:Table S4 and SHANK2). In total, 16 out of 69 genes were
differentially expressed using the Benjamini-Hochberg
method to correct for multiple testing with a false discovery
rate of 10% (Table 1, Additional file 1: Table S5). This
analysis was based on differential expression at the gene
level. Four target genes (4/16; RORA, CPLX1, TCF4, SIRT1)
showed significant expression differences on the whole-
transcriptome level [25]. All study-wide significant miR-137
target genes had modest fold changes with a mean of 1.09
and a range of 1.049–1.135 (inverting downregulated
expression ratios). The majority of differentially expressed
miR-137 target genes (12/16) showed elevated mRNA levels
in SCZ individuals compared with controls. Five of the 12
upregulated genes (TCF4, SIRT1, XIAP, GRIA1, ZNF804A)
had already been associated with SCZ. In addition, genes
linked to ID (TCF4, CPLX1, CDK6, KDM5B), ASD (RORA,
KDM5B), and bipolar disorder (ZNF804A) were also among
the 16 differentially expressed target genes. Elevated mRNA
expression of the SCZ-associated gene GRIA1 has been
described in layer II/III and V pyramidal cells of the DLPFC
in SCZ individuals [32].
In total, 23% of miR-137 targets were differentially
expressed between SCZ and control individuals. We com-
pared the expression of these targets to other microRNA
targets. We selected the following five microRNAs that are
expressed in the DLPFC but are not differentially expressed
in SCZ individuals: let-7a, miR-21-5p, miR-93-5p, miR-
451a, and miR-675-5p. Expression data for these micro-
RNA precursors was not available in the CommonMind
data set. We analyzed the number of validated target genes
Table 1 Experimentally validated miR-137 target genes (summarized in Additional file 1: Table S4) with a significant expression difference
in the DLPFC (dorsolateral prefrontal cortex) between SCZ and control individuals. The log2-fold change and P values were taken from the
analysis published by the CommonMind Consortium (summarized in Additional file 1: Table S5). The log2-fold change was calculated by
adding 1 to the respective values. The Benjamini-Hochberg method was used to correct for multiple testing with a false discovery rate of
10%. SCZ schizophrenia, ASD autism spectrum disorders, BD bipolar disorder, ID intellectual disability
Gene symbol Ensemble ID Log2-fold change P value Association to neurodevelopmental/
neuropsychiatric disease
Ref.
RORA ENSG00000069667 1.118 1.21E−05 ASD candidate [43]
CPLX1 ENSG00000168993 0.820 4.60E−04 Wolf Hirschhorn syndrome [44]
TCF4 ENSG00000196628 1.063 4.97E−04 SCZ, Pitt-Hopkins syndrome [18, 45]
SIRT1 ENSG00000096717 1.074 5.59E−04 SCZ [46]
ESRRA ENSG00000173153 0.888 2.72E−03
CDK6 ENSG00000105810 1.087 3.86E−03 Microcephaly [47]
XIAP ENSG00000101966 1.060 4.68E−03 SCZ [48]
ZNF804A ENSG00000170396 1.108 5.29E−03 SCZ, BD [49]
MET ENSG00000105976 1.132 5.34E−03
CTBP1 ENSG00000159692 0.936 5.77E−03
GRIA1 ENSG00000155511 1.068 8.78E−03 SCZ [32, 50]
KLF12 ENSG00000118922 1.066 1.10E−02
MSI1 ENSG00000135097 0.865 1.23E−02
KDM5B ENSG00000117139 1.049 1.45E−02 ID, ASD [51]
PAQR3 ENSG00000163291 1.067 1.71E−02
TRIM13 ENSG00000204977 1.050 2.28E−02
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revealed a lower frequency compared with the respective
miR-137 targets (Additional file 1: Table S6, differentially
expressed targets: let-7a 14%, miR-21-5p 11%, miR-93-5p
14%, miR-451a 0%, and miR-675-5p 0%). The numbers
of differentially expressed target genes were signifi-
cantly different between miR-137 and the five pooled
controls (P = 0.031, Χ2 test, two-sided, Yates correction,
Additional file 1: Table S6).
miR-137 acts cooperatively and synergistically with miR-
124 and miR-128 [7, 33, 34]; therefore, changes in the
expression of these two microRNAs may interfere with the
expression of miR-137 target genes. We analyzed the
precursor expression of both microRNAs in the Com-
monMind data set and found no evidence of differential
expression. MIR124-2HG (ENSG00000254377) expression
was not different between SCZ and control individuals
(P = 0.8487, expression level 5.948). No data was available
for MIR-128 (ENSG00000207654, ENSG00000207625) or
for mature microRNAs. To investigate possible co-
regulation with miR-137, we looked for additional binding
sites in the 3′UTR of differentially expressed miR-137 tar-
get genes (Table 1). Several targets listed in Table 1 had
putative binding sites for miR-124 (5 out of 16) and miR-
128 (1 out of 16) (Additional file 1: Table S7).
Finally, we performed a functional network analysis of
validated miR-137 targets (Table 2). Genes involved in celldeath and survival, cellular movement, gene expression,
and molecular transport were enriched. Many target genes
were linked to developmental disorders, neurological
diseases, and psychological disorders among which SCZ
turned out to be the top hit.
Discussion
In this study, we identified SHANK2 as a novel direct
target of miR-137. We discovered that physiological levels
of miR-137 regulate SHANK2 expression, most likely by
repressing translation of SHANK2 protein rather than
inducing mRNA degradation. Inhibiting effective protein
translation is a known mechanism for local fine tuning of
gene expression at postsynaptic sites and is in line with
previously reported direct miR-137 targets, including
Ephrin B2 (EFNB2) and the AMPA receptor subunit
GluA1 (GRIA1) [35, 36]. miR-137 regulates the expression
of several proteins that function at glutamatergic synapses,
e.g., EFNB2, GluA1, and Mib1 and thereby influences
neuronal maturation and signal transduction [8, 35, 36].
AMPA receptors are anchored to the postsynaptic Shank
scaffold via PSD-95/Stargazin proteins [37]. SHANK2 and
AMPA receptors are both regulated by miR-137 and are
important for synaptic maturation and plasticity; there-
fore, this control by miR-137 may have synergistic effects
on synaptic regulation. Beside the regulation of postsynap-
tic genes, miR-137 has also been shown to regulate
Table 2 Ingenuity pathway analysis of the 71 previously published experimentally validated miR-137 targets
Category Diseases and functions Number of molecules P value
Cell death and survival Cell death 48 6.43 × 10−16
Apoptosis 46 8.91 × 10−19
Necrosis 41 3.42 × 10−14
Neuronal cell death 17 5.74 × 10−9
Cellular movement Cell movement 39 1.53 × 10−15
Migration of cells 35 7.17 × 10−14
Gene expression Transcription of RNA 34 6.14 × 10−14
Expression of RNA 36 2.90 × 10−13
Transcription of DNA 29 4.30 × 10−12
Molecular transport Transport of molecule 23 4.69 × 10−7
Secretion of molecule 17 1.53 × 10−10
Secretion of neurotransmitter 9 5.53 × 10−9
Developmental disorders Abnormal morphology of embryonic tissue 17 2.36 × 10−10
Growth failure 14 3.30 × 10−7
Dysgenesis 13 5.57 × 10−7
Neurological disease Schizophrenia 14 7.63 × 10−9
Cell death of cortical neurons 9 2.38 × 10−8
Congenital malformation of brain 9 6.18 × 10−6
Brain cancer 8 2.38 × 10−6
Apoptosis of cortical neurons 7 2.75 × 10−8
Neurodegeneration of pyramidal neurons 3 3.94 × 10−6
Psychological disorders Schizophrenia 14 7.63 × 10−9
Disorder of basal ganglia 12 2.10 × 10−4
Mood disorders 9 8.92 × 10−5
Major affective disorder 8 1.97 × 10−4
Depressive disorder 7 1.49 × 10−4
Dyssomnia 4 1.43 × 10−4
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lease [38]. This is supported by the finding that altered
miR-137 levels impact synaptic function and neuronal net-
work formation in the mouse hippocampus [36].
Morphological effects caused by altered Shank2 levels
in hippocampal neurons do not correlate to the morpho-
logical changes found when miR-137 levels are altered.
Overexpression of SHANK2 increased spine volume
while its downregulation led to reduced spine volume
and increased dendritic arborization [39]. In contrast,
miR-137 overexpression or inhibition did not affect
dendritic spine morphology, whereas miR-137 inhibition
only led to a reduced spine density [36]. This difference
might be due to a more subtle regulatory effect of miR-
137 on Shank2 protein expression compared to an
RNAi-mediated knockdown as microRNAs are “fine-
tuners” of protein expression. miR-137 regulates the
expression of multiple glutamatergic synapse proteins;
therefore, subtle regulation of SHANK2 expression bymiR-137 is likely to be physiologically relevant. miR-137
also has subtle effects on the protein expression of its
other targets [36]. Different postsynaptic proteins are
probably regulated by miR-137 at the same time, which
may increase the intensity of the neuronal response.
We showed a regulatory influence of miR-137 on
SHANK2 expression in mouse hippocampal neurons,
whereas the relevance in other brain regions and in
human neurons warrants future investigation.
miR-137 has been linked to various disorders including
ID, ASD, and SCZ [6, 10, 11, 18]. Impaired synaptic
plasticity and glutamatergic neurotransmission have been
postulated as underlying pathological mechanisms [40]. A
heterozygous microdeletion on 1q21.3 encompassing the
genes MIR137 and DPYD was previously described in ID
and ASD patients [6, 10, 11]. Reduced levels of precursor
and mature miR-137 concurrently with significantly
increased levels of downstream target genes (MITF, EZH2,
and KLF4) were determined in lymphoblastoid cells
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[6]. Based on our experimental results, we speculate that
reduced miR-137 expression may also increase SHANK2
levels in these patients, which may contribute to the ID
and ASD phenotype seen in these patients.
To further investigate the link between miR-137 and
SCZ, we analyzed the expression of miR-137 precursor
and known miR-137 target genes in postmortem DLPFC
samples of SCZ individuals using the CommonMind gene
expression data resource [25]. No difference in miR-137
precursor expression was found between SCZ and control
individuals. Our study was limited to miR-137 precursor
expression analysis as no data of mature miR-137 expres-
sion was available. Previous studies have shown no differ-
ence in the levels of precursor and mature miR-137
between SCZ and control individuals [31, 41, 42]. miR-
137 expression has been investigated in fibroblasts and
fibroblast-derived neurons isolated from individuals
homozygous for four schizophrenia-associated SNPs at
the MIR137 locus. Increased endogenous miR-137 levels
were identified in the minor compared to the major allele
SNP group in the neurons, but not in fibroblasts [38]. This
indicates that regulation of miR-137 expression varies in
different cell types. Analyzing miR-137 expression in
specific cortical layers, cell types, or even cell compart-
ments might reveal distinct local alterations in the DLPFC
of SCZ patients.
Our network analysis revealed that many validated miR-
137 target genes are linked to developmental, neurological,
and psychiatric disorders, particularly SCZ. Therefore, we
analyzed the expression of these genes in the DLPFC, a
brain region that is affected in SCZ individuals. Expression
of 23% (16/69) of the analyzed target genes was altered in
the DLPFC of SCZ compared with control individuals. This
change in expression was above the level of target enrich-
ment in a pooled sample of five control microRNAs. This
indicated that the miR-137 signaling network might be
altered in the DLPFC of SCZ individuals. Five of these
differentially expressed target genes have been associated
with SCZ (TCF4, SIRT1, XIAP, GRIA1, ZNF804A) and two
with ASD (RORA, KDM5B), suggesting some overlap
between these two disorders. Four miR-137 target genes
(RORA, CPLX1, TCF4, SIRT1) even show significant differ-
ences on the whole-transcriptome level, according to data
provided by the CommonMind Consortium [25]. Further-
more, analysis of the CommonMind RNA sequencing data
confirmed elevated GRIA1 mRNA levels in the DLPFC of
SCZ individuals [32], indicating impaired synaptic signaling
in the DLPFC. The majority of differentially expressed miR-
137 target genes (12/16) were only modestly elevated in
SCZ individuals, suggesting that small effects of single
genes accumulate in the DLPFC, presumably leading to a
general impairment of miR-137 signaling. It is important to
note that expression of miR-137 target genes is notregulated by miR-137 alone, but by multiple factors, e.g.,
other microRNAs, epigenetic mechanisms, subcellular
localization, synaptic activity, medication, or other environ-
mental factors. We analyzed miR-124 and miR-128, which
act cooperatively with miR-137, and obtained no evidence
that these two microRNAs influence the differential expres-
sion of miR-137 targets. miR-124 precursor expression was
not different between SCZ and control individuals and the
differentially expressed miR-137 target genes may only
slightly be co-regulated by miR-124 and miR-128. Only
23% of the analyzed miR-137 target genes were differen-
tially expressed on the mRNA level between SCZ and
control individuals. Most miR-137 targets have been inves-
tigated in cancer cell lines and only 13 miR-137 target
genes (including SHANK2) have been confirmed in
neuronal cells; therefore, some of the confirmed targets
may not be miR-137 targets in the brain. Expression of
SHANK2 mRNA was not different in the DLPFC of SCZ
and control individuals, which may mean that SHANK2 is
not a relevant miR-137 target in the context of SCZ.
However, we and others have identified neuronal miR-137
target genes which were regulated on protein [35, 36] and
not on mRNA level. Therefore, we conclude that changes
in mRNA expression do not reveal the full regulatory
potential of miR-137. In this regard, proteomic data from
postmortem human brains will be of high value for future
SCZ studies.
Conclusions
We identified a direct regulatory link between microRNA-
137 and SHANK2, which is of importance for a spectrum
of disorders including ID, ASD, and SCZ. Furthermore,
evidence was obtained that miR-137 target genes are
differentially expressed between healthy controls and SCZ
patients offering additional support for the involvement of
miR-137 and its target genes in the pathogenesis of neuro-
psychiatric disorders. Further studies are warranted to
address the mutual interaction in conditional knockout
mouse models or human-induced pluripotent stem cell-
derived neurons.
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